Brief Summary: The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can result in rashes or tumors in the skin. This study includes a 24 week Treatment Period and a 24 week Follow-up Period. This study will involve physical examinations, visual assessments, laboratory tests, PET-CT scans, electrocardiograms, photographs of your skin, skin biopsies, and hearing tests.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Website: https://www.clinicaltrials.gov/study/NCT05879458?term=Ritlecitinib%20in%20CTCL&rank=1

Sponsor: Icahn School of Medicine at Mount Sinai

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.

Please refer to this study by its ClinicalTrials.gov identifier: NCT05879458